Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 18 to 55

Trying increasing single and repeated doses of SRK-439 in healthy adults

Official title: A Phase 1 Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRK-439 in Healthy Adults

Run by Scholar Rock, Inc. · NCT07444294 · Data updated 2026-11-12

This trial tests whether different single and repeated doses of SRK-439 are safe and how the body handles the drug in healthy adults.

More Healthy Aging trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years to 55 Years
SexAll
Enrollment76 (estimated)
SponsorScholar Rock, Inc.
Industry-sponsored
Drugs / interventionsapitegromab, radiation
Locations1 site (Cincinnati, Ohio)
StatusRecruiting
StartedNovember 21, 2025
Main results expectedDecember 17, 2026
Study endsJune 9, 2027
Registry record updatedMarch 2, 2026
Trial IDNCT07444294 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are healthy men or women aged 18 to 55 with a BMI of 18–35 kg/m2 who are not taking muscle-active drugs and have not previously received SRK-439 or other anti-myostatin therapies.

Probably not a fit

People seeking immediate treatment for a medical condition, those currently using anabolic steroids, growth hormones, or other muscle-altering therapies, or those with recent immunosuppressive or certain antibody exposures are unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, single- and multiple-ascending dose study in healthy adults that examines safety, tolerability, pharmacokinetics, and pharmacodynamics of SRK-439. Participants will receive either SRK-439 or placebo in sequential dosing cohorts with doses increasing between cohorts. Both single-dose and repeated-dose regimens are included to characterize short-term and repeat-exposure effects. Safety monitoring and blood sampling for PK/PD analyses will be performed throughout the dosing and follow-up periods.

Why it matters

Potential benefit: If successful, this work could speed development of SRK-439 and similar drugs that aim to protect or build muscle, potentially helping people with muscle-wasting conditions.

How similar studies have gone: Other anti-myostatin and related pathway agents have shown some promising biological signals in early trials, but results have varied and this specific compound remains early in clinical testing.

Who can join: the full rules

Show full inclusion / exclusion criteria
Key Inclusion Criteria:

1. Male or female participants, ≥18 to ≤55 years of age, at the time of informed consent
2. BMI of ≥18 kg/m2 to ≤35 kg/m2 (inclusive) at screening

Exclusion Criteria:

1. Previous treatment with SRK-439 or apitegromab, or with other anti-myostatin therapies, including ACTR antagonists.
2. History of immunosuppressive, chemotherapeutic, or radiation treatment within 12 months prior to screening.
3. Current or prior use of anabolic steroids, growth hormones, or other substances with known effects on muscle.
4. Use of therapies with potentially significant muscle effects (eg, insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form within 3 months prior to screening or during the study.
5. Any history of exposure to a mAb or Fc domain-bearing recombinant protein within 5 years prior to screening with any prior history of hypersensitivity reactions from exposure
6. Treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic within 3 months or 5 half-lives, whichever is longer, prior to screening.

Where it's running

  • Medpace CPU
    Cincinnati, Ohio, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.